These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 17785569

  • 1. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
    Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
    Clin Cancer Res; 2007 Sep 01; 13(17):5144-9. PubMed ID: 17785569
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
    Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I.
    Clin Cancer Res; 2009 Aug 15; 15(16):5274-9. PubMed ID: 19671873
    [Abstract] [Full Text] [Related]

  • 4. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
    Hassan R, Alewine C, Mian I, Spreafico A, Siu LL, Gomez-Roca C, Delord JP, Italiano A, Lassen U, Soria JC, Bahleda R, Thomas A, Steinberg SM, Peer CJ, Figg WD, Niederfellner G, Méresse Naegelen V, Pastan I.
    Cancer; 2020 Nov 15; 126(22):4936-4947. PubMed ID: 32870522
    [Abstract] [Full Text] [Related]

  • 5. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
    Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, Tsang KY, Surawski RJ, Scott T, Camphausen K.
    Clin Cancer Res; 2006 Aug 15; 12(16):4983-8. PubMed ID: 16914588
    [Abstract] [Full Text] [Related]

  • 6. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
    Li Q, Verschraegen CF, Mendoza J, Hassan R.
    Anticancer Res; 2004 Aug 15; 24(3a):1327-35. PubMed ID: 15274292
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
    Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh J, Zhang Y, Ingle GS, Fourie-O'Donohue A, Kozak KR, Ross S, Dennis MS, Spencer SD.
    Mol Cancer Ther; 2014 Nov 15; 13(11):2630-40. PubMed ID: 25249555
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
    Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J.
    Clin Cancer Res; 2007 Dec 01; 13(23):7166-71. PubMed ID: 18056197
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
    Liu XF, Xiang L, FitzGerald DJ, Pastan I.
    Mol Cancer Ther; 2014 Jan 01; 13(1):82-9. PubMed ID: 24145282
    [Abstract] [Full Text] [Related]

  • 12. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
    Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R.
    Anticancer Res; 2012 Dec 01; 32(12):5151-8. PubMed ID: 23225411
    [Abstract] [Full Text] [Related]

  • 13. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
    Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
    Mol Cancer Ther; 2013 Jan 01; 12(1):48-57. PubMed ID: 23136186
    [Abstract] [Full Text] [Related]

  • 14. SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors.
    Leshem Y, King EM, Mazor R, Reiter Y, Pastan I.
    Toxins (Basel); 2018 Nov 14; 10(11):. PubMed ID: 30441807
    [Abstract] [Full Text] [Related]

  • 15. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
    Zhang YF, Phung Y, Gao W, Kawa S, Hassan R, Pastan I, Ho M.
    Sci Rep; 2015 May 21; 5():9928. PubMed ID: 25996440
    [Abstract] [Full Text] [Related]

  • 16. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
    Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M.
    PLoS One; 2011 Jan 31; 6(1):e14640. PubMed ID: 21305058
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH, Zamboni WC, Tait NS, Meisenberg BR, Doyle LA, Edelman MJ, Hausner PF, Egorin MJ, Van Echo DA.
    Cancer Chemother Pharmacol; 2000 Jan 31; 46(6):442-8. PubMed ID: 11138457
    [Abstract] [Full Text] [Related]

  • 18. Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine.
    Liu XF, Wei J, Zhou Q, Molitoris BA, Sandoval R, Kobayashi H, Okada R, Nagaya T, Karim B, Butcher D, Pastan I.
    Proc Natl Acad Sci U S A; 2020 Mar 17; 117(11):6086-6091. PubMed ID: 32123080
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
    Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS.
    Clin Cancer Res; 2002 Dec 17; 8(12):3686-95. PubMed ID: 12473577
    [Abstract] [Full Text] [Related]

  • 20. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML.
    Clin Cancer Res; 1997 Mar 17; 3(3):409-17. PubMed ID: 9815699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.